Skip to main content

Meet Clyde

Clyde was diagnosed with severe hemophilia A at birth. Growing up, he felt different, and all he wanted was to be like other kids. He attended hemophilia camps but reached a point where he no longer wished to be involved in the community—until he reached college age, when he realized that hemophilia is part of who he is. He embraced his bleeding disorder and became active with the hemophilia community. With 2 nephews who also live with hemophilia, Clyde strives to provide a good example by taking care of himself. He encourages his nephews and others living with hemophilia to take advantage of opportunities to have fun and just be themselves while managing their bleeding disorder.

Please see full Prescribing Information.

Individual results may vary.

Play
Pause
Skip
Volume
Chapters
Transcript
References
Subtitles
Fullscreen

Meet Clyde

Chapters
Transcript
References

Clyde was diagnosed with severe hemophilia A at birth. Growing up, he felt different, and all he wanted was to be like other kids. He attended hemophilia camps but reached a point where he no longer wished to be involved in the community—until he reached college age, when he realized that hemophilia is part of who he is. He embraced his bleeding disorder and became active with the hemophilia community. With 2 nephews who also live with hemophilia, Clyde strives to provide a good example by taking care of himself. He encourages his nephews and others living with hemophilia to take advantage of opportunities to have fun and just be themselves while managing their bleeding disorder.

Please see full Prescribing Information.

Individual results may vary.

Return to overview

Transcripts

Return to overview

References


Selected Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment

Indications and Usage

Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Novoeight® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment
  • Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors

Adverse Reactions

  • The most frequently reported adverse reactions (≥1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia.

Please click here for Prescribing Information.